SCHEMBL5263340

SCHEMBL5263340

O=Cc1c[nH]c2nc(OC(=O)c3ccccc3)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.43
PIM1 P11309 2/20 0.39
PIM3 Q86V86 2/20 0.39
MAPT P10636 6/20 0.39
CYP2A6 P11509 1/20 0.38
IMPDH2 P12268 1/20 0.38
HSD17B10 Q99714 2/20 0.38
PARP1 P09874 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
LMNA P02545 1/20 0.36
METAP2 P50579 1/20 0.36
METAP1 P53582 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 3/20 0.36
JAK2 O60674 1/20 0.36
USP2 O75604 1/20 0.36
ESR1 P03372 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5260576 0.85 AKR1C1 (0.38) KMT2AMAPTHSD17B10PARP1SMN1; SMN2
SCHEMBL5261547 0.85 AKR1C1 (0.38) KMT2AMAPTHSD17B10PARP1SMN1; SMN2
SCHEMBL5260583 0.83 MAP3K7 (0.36) KMT2APIM1PIM3MAPTHSD17B10
SCHEMBL5260587 0.83 MAP3K7 (0.36) KMT2APIM1PIM3MAPTHSD17B10
SCHEMBL5261242 0.73 MAP3K7 (0.33) KMT2AHPGDKDM4EMEN1USP2
SCHEMBL5258384 0.72 KMT2A (0.44) KMT2AMAPTHSD17B10PARP1SMN1; SMN2
SCHEMBL15687368 0.71 PIM3 (0.51) KMT2APIM1PIM3MAPTCYP2A6
SCHEMBL29951425 0.71 KMT2A (0.51) KMT2APIM1PIM3MAPTCYP2A6
SCHEMBL20629258 0.70 ALDH1A1 (0.58) KMT2AMAPTCYP2A6IMPDH2SMN1; SMN2
SCHEMBL5263827 0.68 KMT2A (0.54) KMT2APIM1PIM3MAPTCYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP disclosed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US disclosed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS FFAR4, AZI2, CNKSR1 KMT2A 1011/4885PIM1 2854/4885PIM3 2569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.